Contenu disponible en anglais seulement.
Bulletin de la Bourse
Antibe Therapeutics Inc. (ATE) inscrit à la Bourse de Toronto
10 novembre 2020
| Issuer: | Antibe Therapeutics Inc. (the "Company") |
| Security: | Common shares (the "Shares") |
| Symbol: | ATE |
| Number of securities issued and outstanding: | 386,782,798 Shares |
| Number of securities reserved for issuance: | 107,290,215 Shares |
| Trading currency: | CDN$ |
| Listing and posted for trading date: | November 12, 2020 (at the opening) |
| Listing category: | Industrial, Non-Exempt Issuer |
| Other market(s): | The Shares have been listed and trading on TSX Venture Exchange ("TSXV") under their current form since June 18, 2013 and trade under the symbol "ATE". The Shares will be delisted from TSXV on November 12, 2020 upon commencement of trading on Toronto Stock Exchange. |
| Temporary market maker: | Virtu Financial Canada ULC |
| Security ownership registration: | Non-certificated inventory |
| Investor relations: | Christina Cameron (647) 708-2636 Email: christina@antibethera.com Will O'Connor (212) 698-8694 Email: will.oconnor@sternir.com |
| Incorporation: | Business Corporations Act (Ontario) on May 5, 2009 |
| Fiscal year end: | March 31 |
| Nature of business: | The Company is a late-stage biotechnology company that seeks to develop safer medicines for pain and inflammation. |
| Transfer agent and registrar: | Computershare Investor Services Inc. at its principal office in Toronto. |
| Dividends: | The Company has not paid dividends in the past and has no plans to pay dividends for the foreseeable future. |
| Sponsorship: | Not applicable. |
| Disclosure document: | Annual Information Form dated July 23, 2020 which is available at www.SEDAR.com. Capitalized terms not otherwise defined herein are as defined in the disclosure document. |
| TSX contact: | Chris Birkett, Managing Director, Toronto Stock Exchange |